Immunoglobulin G1-kappa, anti-[Homo sapiens CD38 (ADP-ribosyl cyclase 1, cyclic ADP-ribose hydrolase 1, cADPr hydrolase 1, cADPR1)], humanized monoclonal antibody
T-ALL
Institute of Hematology & Blood Diseases Hospital, Chinamonoclonal_antibodyPhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 95/ 100
Competitive context
4 Active assets in the T-ALL cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Isatuximab Goethe University | Phase 2 | CCC |
CD123-CAR T St. Jude Children's Research Hospital | Phase 1 | CC |
Senl101 Hebei Senlang Biotechnology Inc., Ltd. | Phase 1 | CC |
her2bbζ/cd19t+ t cells PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Phase 1 | CC |
6-(4-(1,1-Dimethylethyl)phenoxy)-3-pyridinamine Cellestia Biotech AG | Phase 1/2 | D |
Vgo-Cs01P Shanghai Jiao Tong University School of Medicine | Early Phase 1 | NR |
Same molecule, other indications
Immunoglobulin G1-kappa, anti-[Homo sapiens CD38 (ADP-ribosyl cyclase 1, cyclic ADP-ribose hydrolase 1, cADPr hydrolase 1, cADPR1)], humanized monoclonal antibody is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →